Soligenix’s HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Soligenix develops HyBryte™, a visible light therapy for early-stage cutaneous T-cell lymphoma (CTCL), offering safer treatment with significant clinical efficacy
2026/01/30